SCHEMBL500487

SCHEMBL500487

CC(CC(=O)O)N1CCCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 3/20 0.47
MAPT P10636 2/20 0.47
POLB P06746 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
REN P00797 1/20 0.40
ACE P12821 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
DPP7 Q9UHL4 1/20 0.38
HTT P42858 1/20 0.38
CACNA2D1 P54289 2/20 0.38
CACNB3 P54284 1/20 0.38
CACNA1C Q13936 1/20 0.38
PGR P06401 1/20 0.38
ADRA1A P35348 1/20 0.38
HTR2B P41595 1/20 0.38
CACNA2D2 Q9NY47 1/20 0.38
RAD52 P43351 1/20 0.36
ITGB3 P05106 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL499913 0.98 KDM4E (0.46) KDM4EALDH1A1MAPTPOLBSMN1; SMN2
SCHEMBL5500053 0.98 KDM4E (0.46) KDM4EALDH1A1MAPTPOLBSMN1; SMN2
SCHEMBL4181286 0.91 KDM4E (0.54) KDM4EALDH1A1MAPTPOLBSMN1; SMN2
SCHEMBL1174393 0.91
SCHEMBL3128590 0.83 KDM4E (0.49) KDM4EALDH1A1MAPTPOLBSMN1; SMN2
SCHEMBL500539 0.81 KDM4E (0.44) KDM4EALDH1A1MAPTPOLBSMN1; SMN2
SCHEMBL500092 0.81 ALDH1A1 (0.46) KDM4EALDH1A1MAPTPOLBSMN1; SMN2
SCHEMBL20610094 0.79 ALDH1A1 (0.43) KDM4EALDH1A1MAPTPOLBSMN1; SMN2
Hydrochloric Acid SCHEMBL5174239 0.79 TP53 (0.41) KDM4EALDH1A1SMN1; SMN2L3MBTL1CYP2C19
SCHEMBL1856575 0.78 CYP1A2 (0.50) ALDH1A1MAPTPOLBSMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4267362-A Process for the preparation of delta keto-acids and derivatives thereof STAMICARBON, B.V. (NL) 1981-05-12 US claimed
US-8105760-B2 Patterning process and pattern surface coating composition SHIN-ETSU CHEMICAL CO., LTD. (JP) 2012-01-31 US disclosed
US-20090053657-A1 PATTERNING PROCESS AND PATTERN SURFACE COATING COMPOSITION SHIN-ETSU CHEMICAL CO., LTD. (JP) 2009-02-26 US disclosed
US-20070238721-A1 Highly Selective Novel Amidation Method TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-10-11 US disclosed
EP-1753752-A1 HIGHLY SELECTIVE NOVEL AMIDATION METHOD Takeda Pharmaceutical Company Limited (JP) 2007-02-21 EP disclosed
WO-2005121133-A1 HIGHLY SELECTIVE NOVEL AMIDATION METHOD TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238721-A1 Highly Selective Novel Amidation Method NAAA, CPS1, COASY KDM4E 1441/4885ALDH1A1 1472/4885MAPT 3828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.